Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S.

Dement Geriatr Cogn Disord. 2010;30(2):131-46. doi: 10.1159/000318845. Epub 2010 Aug 21.

2.

Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.

Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M.

Curr Alzheimer Res. 2011 Aug;8(5):592-606.

PMID:
21592048
3.

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD; Rosiglitazone in Alzheimer's Disease Study Group..

Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54. Epub 2006 Jan 31.

PMID:
16446752
4.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
5.
6.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A.

Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019.

7.

Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.

Suh GH, Jung HY, Lee CU, Oh BH, Lee SK, Lee N, Kim J, Kee BS, Ko D, Kim YH, Ju YS, Hong I, Choi S; Korean Galantamine Study Group..

Dement Geriatr Cogn Disord. 2006;21(1):33-9. Epub 2005 Oct 25.

8.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT.

Neurology. 1998 Jan;50(1):136-45.

PMID:
9443470
9.

Donepezil preserves cognition and global function in patients with severe Alzheimer disease.

Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.

Neurology. 2007 Jul 31;69(5):459-69.

PMID:
17664405
11.

Metrifonate treatment of AD: influence of APOE genotype.

Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B.

Neurology. 1999 Dec 10;53(9):2010-6.

PMID:
10599773
12.
13.

Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.

Rogers SL.

Dement Geriatr Cogn Disord. 1998;9 Suppl 3:29-42. Review.

PMID:
9853200
14.

The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.

Kobayashi H, Ohnishi T, Nakagawa R, Yoshizawa K.

Int J Geriatr Psychiatry. 2016 Aug;31(8):892-904. doi: 10.1002/gps.4405. Epub 2015 Dec 17. Review.

PMID:
26680338
15.

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.

Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.

Neurology. 2009 May 5;72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03. Epub 2009 Jan 28.

PMID:
19176895
16.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group..

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
17.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
18.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
19.

APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.

Waring JF, Tang Q, Robieson WZ, King DP, Das U, Dubow J, Dutta S, Marek GJ, Gault LM.

J Alzheimers Dis. 2015;47(1):137-48. doi: 10.3233/JAD-142589.

20.

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.

Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD; Donepezil Study Group..

Arch Neurol. 2001 Mar;58(3):427-33.

PMID:
11255446

Supplemental Content

Support Center